GENPF (Genix Pharmaceuticals) EBITDA Margin %: 0.00% (As of Jan. 2026)


What is Genix Pharmaceuticals EBITDA Margin %?

Genix Pharmaceuticals GENPF EBITDA Margin % is 0.00% as of Jan. 2026. The stock has 3 warning signs investors should review. Among 952 Drug Manufacturers companies, Genix Pharmaceuticals ranks worse than 105041.91% on this metric.

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Genix Pharmaceuticals's EBITDA for the three months ended in Jan. 2026 was $-0.01 Mil. Genix Pharmaceuticals's Revenue for the three months ended in Jan. 2026 was $0.00 Mil. Therefore, Genix Pharmaceuticals's EBITDA margin for the quarter that ended in Jan. 2026 was 0.00%.

Genix Pharmaceuticals  (OTCPK:GENPF) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.

Genix Pharmaceuticals EBITDA Margin % Related Terms

Genix Pharmaceuticals EBITDA Margin % Historical Data

* Premium members only.

The historical data trend for Genix Pharmaceuticals's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Genix Pharmaceuticals EBITDA Margin % Chart

Genix Pharmaceuticals Annual Data
Trend Oct16 Oct17 Oct18 Oct19 Oct20 Oct21 Oct22 Oct23 Oct24 Oct25
EBITDA Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 -30,766.67 1,166.67 0.00

Genix Pharmaceuticals Quarterly Data
Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24 Oct24 Jan25 Apr25 Jul25 Oct25 Jan26
EBITDA Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

GENPF vs ZTS, UTHR: EBITDA Margin % Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Genix Pharmaceuticals's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Genix Pharmaceuticals EBITDA Margin % vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Genix Pharmaceuticals's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Genix Pharmaceuticals's EBITDA Margin % falls into.


Genix Pharmaceuticals EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Genix Pharmaceuticals's EBITDA Margin % for the fiscal year that ended in Oct. 2025 is calculated as

EBITDA Margin %=EBITDA (A: Oct. 2025 )/Revenue (A: Oct. 2025 )
=-0.116/0
= %

Genix Pharmaceuticals's EBITDA Margin % for the quarter that ended in Jan. 2026 is calculated as

EBITDA Margin %=EBITDA (Q: Jan. 2026 )/Revenue (Q: Jan. 2026 )
=-0.008/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBITDA Margin % →
What does a EBITDA Margin % of 0.00% mean?
Genix Pharmaceuticals (GENPF) has a EBITDA Margin % of 0.00% as of Jan. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Genix Pharmaceuticals and its competitors. According to the industry distribution chart, Genix Pharmaceuticals ranks #999999 out of 952 companies in the Drug Manufacturers industry.
Is Genix Pharmaceuticals' EBITDA Margin % too high?
Genix Pharmaceuticals' current EBITDA Margin % is 0.00%. Based on the distribution chart, Genix Pharmaceuticals ranks #999999 out of 952 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers.
How does Genix Pharmaceuticals' EBITDA Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Genix Pharmaceuticals ranks #999999 out of 952 companies for EBITDA Margin %. This places Genix Pharmaceuticals in the lower half of its industry. The industry median EBITDA Margin % is 12.47. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Drug Manufacturers company?
The median EBITDA Margin % among Drug Manufacturers companies is 12.47, based on 952 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Genix Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median EBITDA Margin % is 12.47 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Genix Pharmaceuticals's current EBITDA Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Genix Pharmaceuticals stock overvalued right now?
Genix Pharmaceuticals (GENPF) has a current EBITDA Margin % of 0.00%. The current EBITDA Margin % is 0.00%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Genix Pharmaceuticals (GENPF), the current EBITDA Margin % is 0.00% as of Jan. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Genix Pharmaceuticals Business Description

Other Exchanges GENX:Canada
Address 1055 West Hastings Street, Suite 300, Vancouver, BC, CAN, V6E 1J8
Genix Pharmaceuticals Corp is a Canadian life sciences company focused on the research, development, manufacturing, sales, and distribution of novel, branded generic ophthalmic drugs, and ophthalmic OTC products. It operates as a formulator, manufacturer, licensor, and marketer of life sciences-related products with a focus on nutraceuticals and pharmaceuticals. Its ophthalmic products portfolio comprises different kinds of eye ointments (pending approval), and eye drops. Geographically the company operates only in Canada.